Sponsors & CROs

Patient recruitment and retention for clinical trials

We combine purpose-built technology, data and local insight to accelerate enrollment and keep patients engaged throughout the protocol, with an ethical, patient-centered approach.
Three professionals reviewing study charts and reports together on a table.
Our services

We support the study end to end

The two critical moments of a study: filling enrollment and keeping patients in through the end.
Patient recruitment360° strategies by indication, country and population, with human pre-screening before referral. Sites only see candidates with a real chance.
Retention and engagementSupport for every randomized patient throughout the protocol: we detect dropout risk before it happens and act together with the site.
The challenge

Patients set the study's timeline

With the protocol locked and the sites active, the timeline comes down to two things: reaching patients in time and supporting them through to the end.

Timelines that stretch

A single day of delay in a Phase II or III study costs tens of thousands of USD in direct costs.

Screen failures that drain the site

Candidates who don't qualify consume visits, staff and time from a site that is already at capacity.

Dropout after randomization

A patient who decides to leave the study takes with them the recruitment cost, the visits already done and the study's statistical power.
Why Latin America

The region where enrollment still has room

While traditional markets saturate, Latin America combines patient access, real diversity and data that regulators accept.

Traditional markets have hit their ceiling

Interventional trials went from under 2,000 in 2000 to more than 22,000 in 2020, against an eligible population that did not grow at the same pace. At major centers in the US and Europe, dozens of studies compete for the same patients.

A referral culture among physicians

A Latin American site enrolls roughly 12 participants per trial on average, against about 7 in the United States — some 70% more. Behind that number is a closer physician-patient bond, where raising a trial is a natural part of the clinical conversation.

The diversity regulators are asking for

In US trials of new medicines, representation falls short of each group’s actual weight: 11% of participants were Hispanic against 18.7% of the population. The region brings that diversity within a single operating framework, and its data folds into international regulatory packages.
How we work

From strategy to a patient who completes the study

A process that absorbs the outreach work and stays with the patient after randomization.
1

Analysis and strategy

We study the protocol, the indication and the target population country by country to define where and how to search.
2

Outreach campaigns

Communication tailored to each population and channel: digital media, our referring physician network and patient associations.
3

Human pre-screening

Our team, trained on the protocol, contacts every lead and checks inclusion and exclusion criteria before referring.
4

Support through to the end

Once randomized, the patient stays supported: we spot dropout signals and work an action plan with the site.
Why Un Ensayo para Mí

A partner that knows the region

Technology, local insight and human support to accelerate enrollment and hold on to it.

Purpose-built technology

Advanced analytics and automation to identify and engage the right patients for each protocol, with the patient experience at the center of every decision.

Hyper-localized recruitment

We tailor the strategy to each indication, country and population, combining real-world data with local insight into each country's health system, language and culture.

AI-augmented human support

Local teams using AI-powered tools to support each person empathetically and in real time.

Owned channels

Beyond social media, we run our own patient database, a referring physician network, partnerships with molecular labs and active ties with patient associations.

Quality over volume

We measure qualified candidates, not clicks. The goal is randomization and staying in the study, not a submitted form.

Within the regulatory framework

All of our work follows the protocol and informed consent, under GCP standards and each country's data protection laws.
Compliance

Patient data handled to international standards

We work under Good Clinical Practice and the data protection frameworks international sponsors require.
GCP — Good Clinical PracticeGDPR — General Data Protection RegulationHIPAA — Health Insurance Portability and Accountability ActISO 27001 — Information Security Management
Our information security management practices are aligned with the ISO 27001 standard.
Let's set up a meeting

Tell us about your study

Leave your details and we'll set up a 30-minute call to go over your protocol and where we can help — recruitment, retention or both.
  • We reply within 48 business hours.
  • We set up a 30-minute call with the team that would run the project.
  • If there's a fit, we put together a proposal with scope, timeline and costs.
By submitting this form you agree to be contacted and to the processing of your data under our privacy policy.
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy